Purpose Of Review: Advances in health care over time have led to an evolution in the epidemiology of invasive fungal infections. There is an increasing concern for antifungal resistance and emergence of less common fungal species for which optimal therapies are not well defined. The purpose of this review is to describe mechanisms of antifungal resistance and to evaluate the modern role of new and investigational antifungals.
Recent Findings: Isavuconazole and ibrexafungerp represent the two newest antifungal agents. Evidence from in vivo and in vitro studies has been published recently to help define their place in therapy and potential roles in treating resistant fungi. Isavuconazole is a broad-spectrum triazole antifungal with evidence to support its use in invasive aspergillosis and mucormycosis. Its utility in treating voriconazole-resistant should be confirmed with susceptibility testing if available. Ibrexafungerp is an oral glucan synthase inhibitor with little cross-resistance among currently available antifungals, including echinocandins. It is a promising new agent for invasive candidiasis, including azole-resistant species, and in combination therapy with voriconazole for aspergillosis. Multiple antifungals, some with novel mechanisms, are in development, including rezafungin, oteseconazole, olorofim, fosmanogepix, and opelconazole.
Summary: Both isavuconazole and ibrexafungerp are welcome additions to the arsenal of antifungals, and the prospect of more antifungal options in the future is encouraging. Such an array of antifungals will be important as antifungal resistance continues to expand alongside evolving medical practices. However, managing resistant fungal infections will grow in complexity as the unique role of each new agent is defined.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255453 | PMC |
| http://dx.doi.org/10.1007/s11908-022-00782-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing the effects of Mycozin and Clotrimazole 1% creams on vaginal candidiasis: a triple-blinded randomized controlled trial.
Sci Rep
January 2025
Social Determinants of Health Research Center, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran.
Clotrimazole 1% and Mycozin vaginal cream have been reported to be effective in relieving the symptoms of vulvovaginitis caused by Candida. The resistance to azole compounds, and the side effects of chemical drugs have been reported following azole therapy. It was hypothesized that Mycozin is at least as effective as Clotrimazole in treating vaginal candidiasis.
View Article and Find Full Text PDFCombined application of methyl jasmonate and Bacillus subtilis LLCG89 suppresses blue and green mold of lemon (Citrus limon L.).
Pest Manag Sci
January 2025
Department of Plant Pathology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Background: Bacillus species produce antimicrobial lipopeptides (LPs) and methyl jasmonate (MeJA) induces resistance in harvested fruits against postharvest pathogens. However, there is limited evidence of the combined efficacy of Bacillus LPs and MeJA to suppress postharvest diseases.
Results: This study presents the combined effect of Bacillus LPs and MeJA to suppress P.
Effectiveness of Plant-Induced Resistance Against Root-Knot Nematode Depends on the Policy of Using Inducer on the Host Plant.
Curr Microbiol
January 2025
Department of Horticulture, Agriculture Faculty of Aburaihan, University of Tehran, P.O. Box 11365/4117, Tehran, Iran.
This research was conducted to determine the relationship between plant defense responses and the extent of treatment applied to either the aerial parts or roots of the plant. The experimental treatments included different methods of application (spraying versus soil drenching), varying treatment areas (one-sixth, one-third, half, or all of the plant's aerial parts and roots) with SA, and infecting the plants with root-knot nematodes. Evaluation of plant growth and nematode pathogenicity indices in the greenhouse section, HO accumulation rate, and phenylalanine ammonia lyase enzyme activity (in aerial parts and roots) were carried out in biochemical experiments.
View Article and Find Full Text PDFHumanized Candida and NanoBiT Assays Expedite Discovery of Bdf1 Bromodomain Inhibitors With Antifungal Potential.
Adv Sci (Weinh)
January 2025
Univ. Grenoble Alpes, Inserm, CNRS, Institute for Advanced Biosciences (IAB), Grenoble, 38000, France.
The fungal Bromodomain and Extra-Terminal (BET) protein Bdf1 is a potential antifungal target against invasive fungal infections. However, the need to selectively inhibit both Bdf1 bromodomains (BDs) over human orthologs and the lack of molecular tools to assess on-target antifungal efficacy hamper efforts to develop Bdf1 BD inhibitors as antifungal therapeutics. This study reports a phenyltriazine compound that inhibits both Bdf1 BDs from the human fungal pathogen Candida glabrata with selectivity over the orthologous BDs from the human BET protein Brd4.
View Article and Find Full Text PDFAntifungal susceptibility, clinical findings, and biofilm resistance of Fusarium species causing keratitis: a challenge for disease control.
Braz J Microbiol
January 2025
Federal University of Ceará Fortaleza, Ceará, Brazil.
Fusarium keratitis (FK) is an important clinical condition that can lead to blindness and eye loss, and is most commonly caused by the Fusarium solani species complex (FSSC). This study evaluated the susceptibility of planktonic cells and biofilms of FSSC (n = 7) and non-FSSC (n = 7) isolates obtained from patients with keratitis from a semi-arid tropical region to amphotericin B (AMB), natamycin (NAT), voriconazole (VRZ), efinaconazole (EFZ), and luliconazole (LCZ). Analysis of clinical data showed that trauma was the most common risk factor for FK patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!